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Membrane transporters enable efficient cellular metabolism, aid in nutrient sensing, and
have been associated with various diseases, such as obesity and cancer. Genome-scale
metabolic network reconstructions capture genomic, physiological, and biochemical
knowledge of a target organism, along with a detailed representation of the cellular
metabolite transport mechanisms. Since the first reconstruction of human metabolism,
Recon 1, published in 2007, progress has been made in the field of metabolite transport.
Recently, we published an updated reconstruction, Recon 2, which significantly improved
the metabolic coverage and functionality. Human metabolic reconstructions have been
used to investigate the role of metabolism in disease and to predict biomarkers and
drug targets. Given the importance of cellular transport systems in understanding human
metabolism in health and disease, we analyzed the coverage of transport systems
for various metabolite classes in Recon 2. We will review the current knowledge on
transporters (i.e., their preferred substrates, transport mechanisms, metabolic relevance,
and disease association for each metabolite class). We will assess missing coverage
and propose modifications and additions through a transport module that is functional
when combined with Recon 2. This information will be valuable for further refinements.
These data will also provide starting points for further experiments by highlighting areas
of incomplete knowledge. This review represents the first comprehensive overview of
the transporters involved in central metabolism and their transport mechanisms, thus
serving as a compendium of metabolite transporters specific for human metabolic
reconstructions.
Keywords: human metabolism, transport mechanisms, constraint-based modeling, inborn errors of metabolism,
cancer, metabolic networks and pathways
INTRODUCTION
Membrane transporters mediate the transport of solutes across
cell and organelle membranes. Transport processes can generate
concentration gradients (e.g., active transport process) and mem-
brane potentials (i.e., electrochemical gradient), and they con-
tribute to the regulation of biochemical pathways by maintaining
the cellular concentrations of substrates and products (e.g., GLUT
proteins regulate the availability of glucose). Approximately 2000
genes in the human genome encode for transporters or transport-
related proteins (Brunton et al., 2006). Defective metabolite
transport processes have been associated with various patholog-
ical conditions, including inborn errors of metabolism (IEMs)
(Camacho and Rioseco-Camacho, 1993; Kobayashi et al., 1993;
Seow et al., 2004), obesity (Prudente et al., 2007), and cancer
(Cooper et al., 2003; Macheda et al., 2005). Hence, knowledge of
the cellular transport systems is fundamental to understanding
human metabolism.
Genome-scale metabolic reconstructions (GENREs) integrate
the genomic, physiological, and biochemical knowledge of a
target organism (Palsson, 2006). GENREs are knowledge bases
for metabolites, biochemical transformations/reactions, enzymes
catalyzing the reactions, and genes that encode these enzymes.
GENREs are available for more than 100 organisms, includ-
ing human (Duarte et al., 2007; Thiele et al., 2013). GENREs
can be easily converted into mathematical models and used for
constraint-based modeling and analysis (COBRA), including flux
balance analysis (Orth et al., 2010). Details on the procedures for
GENRE and COBRA modeling are discussed elsewhere (Palsson,
2006; Thiele and Palsson, 2010a; Schellenberger et al., 2011).
The comprehensive biochemical knowledge captured by GENREs
includes gene-protein-reaction associations (GPRs), where indi-
vidual metabolic/transport reactions are represented along with
the genes that encode the enzyme/protein that catalyzes the
reactions. These GPRs are Boolean relationships between the
genes/transcripts and reactions with an “and” or “or” association.
“And” indicates that the expression of all of the genes is necessary
for the reaction(s) to be active (e.g., multi-enzyme complexes
catalyzing a single reaction). An “or” relationship implies that
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any of the genes or gene products can catalyze the reaction (e.g.,
isozymes catalyzing the same reaction).
The first GENRE for human metabolism, Recon 1 (Duarte
et al., 2007), captured the biochemical transformations occurring
in cells in a stoichiometrically accurate manner. These reac-
tions are distributed over seven intracellular compartments (i.e.,
cytoplasm, mitochondrion, Golgi apparatus, endoplasmic retic-
ulum, lysosome, peroxisome, and nucleus). In addition, Recon
1 includes a representation of the extracellular space to account
for the exchanges and transport systems connecting the extra-
cellular space to the cytoplasm. The most recent community
driven global reconstruction of human metabolism, Recon 2
(Thiele et al., 2013), is a substantial expansion over Recon 1
and includes more than 370 additional transport and exchange
reactions/systems. These global reconstructions do not repre-
sent the metabolic capability of a single cell or tissue but rather
are blueprints for all human cells. This reconstruction is anal-
ogous to the human genome, which encodes all of the cellular
functions that may be active in one or more cell-types and
conditions.
A reconstruction represents the metabolic repertoire of an
organism or a cell in a condition-independent manner and
can give rise to multiple condition-specific metabolic models.
Consequently, recent COBRA modeling efforts have focused on
generating cell-type specific metabolic models using cell-type and
condition-specific data (e.g., transcriptomic and metabolomic
data). Cell-type specific reconstructions have been assembled for
cardiomyocytes (Zhao and Huang, 2011; Karlstaedt et al., 2012),
hepatocytes (Gille et al., 2010; Jerby et al., 2010; Bordbar et al.,
2011a), alveolar macrophages (Bordbar et al., 2010), red blood
cells (Bordbar et al., 2011b), renal cells (Chang et al., 2010),
enterocytes of the small intestine (Sahoo and Thiele, 2013), and
different cancer cells (Agren et al., 2012; Jerby et al., 2012). In
addition, the metabolic interactions among cell types, such as
brain cells (Lewis et al., 2010) and hepatocytes, myocytes, and
adipocytes (Bordbar et al., 2011a), have been modeled.
The generation of cell- and tissue-specific reconstructions
requires extensive knowledge about the metabolites that can
be transported across the plasma membranes of such cells.
Transporters connect cells and tissues with their immediate
environment and thus can be used to define the metabo-
lite exchange pattern and, subsequently, which intracellular
metabolic pathways involving these metabolites must be active
to fulfill the chief functions of the cell or tissue. At the same
time, transport reactions are amongst the least well studied
reactions captured in Recon 1 (Duarte et al., 2007), and this
is also the case with Recon 2, despite substantial efforts to
include more transport information. This lack of information
is mostly because the precise function and mechanism cannot
be predicted from sequence data alone for transporter-encoding
genes. We focus this review on plasma membrane transporters
because they are generally better studied than intracellular
transporters.
This review aimed to highlight the extent of our current
knowledge about plasma membrane transporters and how well
these data are captured in Recon 2. First, we introduce general
transport mechanisms, and then we discuss the transport of five
major metabolite classes (i.e., sugar, amino acids, lipids, vitamins,
and others) based on their representation in Recon 2. Ions are
also discussed, although they are not metabolites, because they
are important co-substrates for many transport systems. All of
the transport proteins are listed along with the unique NCBI
EntrezGene identifiers (GeneID) of the encoding gene. At the end,
we discuss the importance of transporters in different metabolic
diseases and cancer. This review is accompanied by a transport
module containing 70 new transport reactions that can be added
to Recon 2. In addition, 24 transport reactions were identified
within Recon 2 that need to be updated with the GPR associa-
tions only to capture the most current knowledge. These updates
are summarized in Supplemental Table S2.
This review does not represent an update of Recon 2, but
rather an expansion of its coverage of plasma membrane trans-
port. The module-based approach permits researchers to actively
contribute to the expansion of human metabolism, while main-
taining Recon 2 as a core GENRE.
GENERAL TRANSPORT MECHANISMS
The cell membrane separates a cell from the extracellular envi-
ronment. While hydrophobic substances can easily cross the lipid
cell membrane by simple diffusion, hydrophilic substances cannot
(Guyton and Hall, 2000). There are two basic modes of cellu-
lar transport for hydrophilic substances (i.e., active and passive).
These basic mechanisms can operate as follows: (1) without a
carrier protein (simple diffusion), (2) with a carrier protein (facil-
itated diffusion), and (3) with the expenditure of energy (primary
and secondary active). The various modes of transport are shown
in Figure 1A.
The cell membrane’s lipophilicity defines the metabolites that
can freely move in and out of the cell, a process called “simple dif-
fusion.” Simple diffusion is directed from a region of high solute
concentration to a region of low solute concentration. Various
factors determine the net rate of diffusion, including the con-
centration difference of the solute, pressure difference between
the cell and the environment, membrane electric potential, and
osmosis (Guyton and Hall, 2000).
Transport processes allowing the passage of a single solute
at a time are referred to as a uniport. “Facilitated diffusion” is
an example of uniport transport (Lodish et al., 2000). In facili-
tated diffusion (also called carrier diffusion), the cargo molecule
itself causes a conformational change in the carrier protein,
which opens a channel for the cargo to cross the cell membrane.
The capacity of this transport mechanism is thereby limited by
the time needed to change the conformation back and forth.
Facilitated diffusion occurs in both directions (Guyton and Hall,
2000).
Active transport is required to move molecules against their
concentration and electrochemical gradients and requires energy
in the form of ATP or other high energy phosphate bonds
(Guyton and Hall, 2000). ATP hydrolysis is either directly con-
nected to the transport (primary active transport) or is gener-
ated as an electrochemical gradient (secondary active transport)
(Alberts et al., 2002; Forrest et al., 2011). When a secondary active
transport process is further coupled to another distinct exchange
mechanism, this process is referred to as tertiary active transport.
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FIGURE 1 | Overview of transport mechanisms and major transport
proteins of the various metabolite classes. (A) The basic modes for
metabolite transport across the plasma membrane are shown. Based on
the energy association, transport processes can be categorized into
active and passive modes based on the energy used. The active mode
can be further classified into primary and secondary mechanisms, while
the metabolites can also be transported mainly via simple diffusion or
facilitated diffusion driven by an increase in entropy. Specialized transport
mechanisms (e.g., receptor-mediated endocytosis and tertiary active
processes) are not shown. (B–G). Highlights major transport proteins
involved in the transport of various substrates belonging to the sugar,
amino acid, lipid, nucleoside, vitamin, and other classes mentioned in the
text. (H) The present work accesses the coverage and gain in membrane
transport systems with reference to the global human metabolic
reconstruction, Recon 2 over Recon 1. The review of the relevant
scientific literature led to the generation of transport reaction module that
contained the proposed additions and modifications, discussed throughout
the text. Refer to the text for a further explanation of these transport
processes. The color coding for the transport mechanism as shown in
(A) has been maintained in the other panels.
One example is the coupling of amino acid transport system A
(SNAT2) with system L (LAT1/4f2hc) for leucine uptake. SNAT2
utilizes the electrochemical gradient established by the Na+/K+
ATPase pump to drive its substrate into the cell (Baird et al.,
2009).
Symport is the transport of multiple solutes across the cell
membrane at the same time and in the same direction. If the
inward transport of one solute is connected to the outward trans-
port of another solute, the process is referred to as antiport
(Alberts et al., 2002).
OVERVIEW OF EXTRACELLULAR TRANSPORT REACTIONS IN HUMAN
GENREs
Recon 1 and Recon 2 are based on manually assembled biochem-
ical knowledge, and their reactions are extensively annotated with
literature evidence (Figure 2A). These GENREs contain 537 and
1537 extracellular transport reactions, respectively. The majority
(89%) of the reactions in Recon 2 were supported by litera-
ture evidence to varying degrees. In this review, the metabolites
are grouped into ten classes as in Recon 2 (Figure 2B). The
amino acid class has the highest number of transport reactions,
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FIGURE 2 | Overview of transport reactions captured in the human
metabolic reconstructions.The transporter content for the major
metabolite classes captured by Recon 2 and Recon 1 are shown and
compared. (A) Quantitative assessment of the transport reactions present
in Recon 1 (Duarte et al., 2007) and Recon 2 (Thiele et al., 2013). (B)
Classification of the transport reactions as per the major class of
metabolite transported. (C) Literature support for the transport reactions
present in Recon 2. (D) The metabolites were divided into ten metabolite
classes and their major transport mechanisms, as captured in Recon 2, are
shown. The blood groups comprise the major glycolipids. (E) Comparison
of the transport reactions present in Recon 1 and Recon 2. The increased
information included and expanded the scope of Recon 2, over Recon 1,
resulting in better transporter coverage for the amino acid, carbohydrate,
and vitamin classes, while significant work is needed for the lipid class.
The following symbols are used:   , good coverage; , intermediate
coverage; , needs significant effort.
many of which have supporting evidence (Figure 2C). In contrast,
the literature support for transport reactions in the “others,”
“xenobiotics,” and “hormone” group was low. Such confidence
gaps arise during the reconstruction process when information
on the transport mechanism is not available, yet physiological evi-
dence for the transport of a metabolite across the cell membrane
has been reported or suggested (e.g., by body fluid or exo-
metabolomic data). In such cases, the corresponding diffusion
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reactions are added to the reconstruction (Thiele and Palsson,
2010a). This lack of information regarding carrier proteins and
mechanisms explains the high number of diffusion reactions for
lipophilic metabolites falling into the “others,” “hormones,” and
“lipids” groups in Recon 2 (Figure 2D). These gaps need to be
filled as more knowledge is obtained (Figure 2E).
TRANSPORT OF SUGARS
Carbohydrates form a major part of the human diet.
Polysaccharides, such as starch, are broken down into sim-
ple sugars in the intestinal lumen. Glucose, galactose, and
fructose are the chief monosaccharides absorbed by enterocytes.
From the enterocytes, sugars are released into the portal blood.
Two main groups of sugar transporters exist, sodium/glucose
co-transporters (SGLTs) and facilitated glucose transporters
(GLUTs). Both groups are encoded by solute carrier (SLC) genes,
where “SLC” is the initial official gene symbols (see Table 1).
The SGLT (SGLT-1 to SGLT-6) family of transporters transport
sugars coupled with sodium ions (secondary active transport). In
contrast, the GLUT (GLUT-1 to GLUT-14) transporters mediate
facilitated diffusion (Wu and Freeze, 2002; Wood and Trayhurn,
2003; Augustin, 2010). Some cells express both transporters for
the uptake and secretion of simple sugars (see below).
SGLT transporters
SGLT-1 (SLC5A1, GeneID: 6523) is located on the apical side
of enterocytes and renal tubules and mediates the influx of glu-
cose and galactose via symport coupled with two sodium ions
(Wood and Trayhurn, 2003; Gropper et al., 2009) (Figure 1B).
The transporter is energized by the sodium gradient established
by the Na/K-ATPase located on the basolateral surface (Hediger
et al., 1995). However, under conditions of decreased lumi-
nal pH, proton-coupled glucose transport by SGLT-1 can take
place (Thwaites and Anderson, 2007). The affinity of the trans-
porter for glucose is reduced under these circumstances (Thwaites
and Anderson, 2007). SGLT-2 (SLC5A2, GeneID: 6524)-mediated
sugar re-absorption has been described in renal cells. SGLT-2
has a low affinity but high capacity for glucose and galactose
transport (Hummel et al., 2011). SGLT-3, also called SAAT1
(SLC5A4, GeneID: 6527), is expressed in cholinergic neurons,
small intestinal cells, and skeletal muscle cells. So far, the only
confirmed function for SGLT-3 in humans is as a glucose sen-
sor by depolarization of the membrane in the presence of high
glucose (Diez-Sampedro et al., 2003). However, in C. elegans,
a single amino acid substitution (from glutamate to glutamine)
enables the protein to behave as a glucose transporter with trans-
port properties similar to SGLT-1 (Bianchi and Diez-Sampedro,
2010). In addition, recent reports have claimed that SGLT-3 is a
glucose-stimulated Na+ transporter (Kothinti et al., 2012). SGLT-
4 (SLC5A9, GeneID: 200010) is a sodium-dependent mannose
transporter, which also has affinity for 1,5-anhydro-glucitol and
fructose (Tazawa et al., 2005). SGLT-4 is highly expressed in the
small intestines and kidneys, but moderately in the liver (Tazawa
et al., 2005). SGLT-5 (SLC5A10, GeneID: 125206) mediates the
sodium-dependent uptake of sugars with the highest affinity for
mannose, followed by fructose, and a very low affinity for glu-
cose and galactose (Grempler et al., 2012). SGLT-5 is expressed
Table 1 | Sugar transporters.
Encoding genes Encoding genes Transport Substrates
(Gene symbols) (EntrezGene IDs) proteins
GLUTs
SLC2A1 6513 GLUT-1 /1 Glucose,
dehydro-ascorbic
acid
SLC2A2 6514 GLUT-2 /1 Glucose, fructose,
glucosamine
SLC2A3 6515 GLUT-3 /1 Glucose,
dehydro-ascorbic
acid
SLC2A4 6517 GLUT-4 /1 Glucose,
dehydro-ascorbic
acid
SLC2A5 6518 GLUT-5 /2 Fructose, glucose
(very low affinity)
SLC2A6 11182 GLUT-6 /3 Glucose
SLC2A7 155184 GLUT-7 /2 Glucose, fructose
SLC2A8 29988 GLUT-8 /3 Glucose (glucose
transporter activity
is inhibited by
fructose and
galactose)
SLC2A9 56606 GLUT-9 /2 Glucose
SLC2A10 81031 GLUT-10 /3 Glucose
SLC2A11 66035 GLUT-11 /2 Glucose, fructose
SLC2A12 154091 GLUT-12 /3 Glucose
SLC2A14 144195 GLUT-14 /1 Glucose
SLC2A13 114134 HMIT /3 Myo-inositol
SGLTs
SLC5A9 200010 SGLT4 Mannose, 1,5-
anhydro-glucitol,
fructose
SLC5A3 6526 SMIT Myo-inositol
SLC5A1 6523 SGLT1 Glucose, galactose
SLC5A2 6524 SGLT2 Glucose, galactose
SLC5A4 6527 SGLT3
(under
amino acid
substitution)
Glucose
SLC5A10 125206 SGLT5 Mannose, fructose,
glucose, galactose
SLC5A11 115584 SGLT6 Glucose,
myo-inositol
The data were assembled from Wood and Trayhurn (2003), Scheepers et al.
(2004), & Thorens and Mueckler (2010). Yellow shading indicates genes encod-
ing either absent transport proteins or transport proteins with limited substrate
specificity in Recon 2. Blue shading indicates improvement in the transporter
data (either the addition of the protein and its associated reactions, the expan-
sion of its substrates, or modification of the GPRs) in Recon 2 over Recon 1.
Transport proteins column also includes the corresponding GLUT class after the
slash. Details of existent sugar transport reactions for Recon 2 are shown in
Supplemental Table S1.
in the kidneys. SGLT-6 (SLC5A11, GeneID: 115584) is a glu-
cose and myo-inositol transporter. Compared to other tissues,
SGLT-6 is the most highly expressed in the brain (Chen et al.,
2010). The sodium myo-inositol co-transporter, SMIT (SLC5A3,
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GeneID: 6526), is expressed ubiquitously and at a high level in
cells lining the blood vessels, the kidneys, and the thyroid gland
(Chen et al., 2010). For a more elaborate tissue distribution for all
of the SGLTs, see recent review by Wright et al. (2011).
GLUT transporters
The GLUT transporters have traditionally been divided into
three families based on sequence similarity (Joost and Thorens,
2001; Scheepers et al., 2004) (Figure 1B). Wilson-O’Brien et al.
proposed dividing the mammalian GLUT transporters into five
distinct classes, subdividing class three proteins into three new
classes [i.e., GLUT-6 and GLUT-8, GLUT-10 and GLUT-12,
and the H+/myo-inositol transporter (HMIT)] (Wilson-O’Brien
et al., 2010). Most of the GLUT transporters have been shown
to transport glucose, with GLUT-2, GLUT-5, and GLUT-11 also
transporting fructose, while HMIT also transports myo-inositol
(Table 1). The transport of other non-carbohydrate substrates by
the GLUT transporters has also been reported. Examples include
uric acid transport by GLUT-9 (Doblado and Moley, 2009) and
dehydroascorbate transport by GLUT-1 to GLUT-4 and GLUT-8
(Cura and Carruthers, 2012; Corpe et al., 2013). Only GLUT-
4, GLUT-8, and GLUT-12 have been shown so far to exhibit
insulin sensitivity (Wood and Trayhurn, 2003). Most of the GLUT
transporters are expressed in the brain, which depends largely on
glucose as an energy source (Vannucci et al., 1998; Bakirtzi et al.,
2009).
Sugar transporters and Recon 2
The transport of sugars is generally well captured by Recon 2. In
total, 80% (60/75 reactions) of the sugar transport reactions in
Recon 2 are supported by literature evidence (Figure 2C). While
the reactions for SGLT-1-mediated transport were added in Recon
2 (Gropper et al., 2009), the transport functions of the other
SGLTs are still missing (Table 1). For instance, while SGLT-2-
mediated glucose transport is captured in Recon 2, its galactose
transport capability (Hummel et al., 2011) is not accounted for.
Moreover, SGLT-5 is only associated with glucose transport, but
not its additional substrates mannose, fructose, and galactose
(Grempler et al., 2012). Finally, SGLT-6 is only associated with
inositol but not glucose transport (Chen et al., 2010). The trans-
port of galactose, mannose, fructose, and glucose already exists in
Recon 2 with the correct transport mechanism; hence, only new
genes have to be added to the GPRs of the corresponding reactions
(see Table 1 and Supplemental Table S2).
TRANSPORT OF AMINO ACIDS
Ingested proteins represent the body’s main source of amino acids
and peptides. Usually, multiple amino acids have the same trans-
port protein (Table 2). The transport systems for both amino
acids and peptides are discussed in this section.
Amino acid transporters
Eleven different SLC families are known to be involved in the
transport of amino acids either via antiport or symport (Broer
and Palacin, 2011) (Figure 1C). There is considerable overlap in
their substrate specificity (Table 2). Transporters in the SLC3 and
SLC7 families form heteromeric protein complexes composed of
heavy and light subunits (SLC3 genes encode the heavy subunit
and SLC7 genes encode the light subunit of the transport pro-
tein) that interact through disulfide bridges. The heavy subunit
is a glycosylated membrane protein; hence, these transporters are
also called glyco-protein-associated amino acid transporters. The
light subunit is required to confer specific amino acid transport
activity (Palacin et al., 2005). The light subunit is fully functional
even in the absence of the heavy subunit. The heteromeric amino
acid transporters are usually amino acid exchangers (antiports)
(Palacin et al., 2005). However, the alanine-serine-cysteine trans-
porter (Asc-type amino acid transporter 1), a heteromeric amino
acid transporter, with a heavy subunit encoded by SLC3A2
(GeneID: 6520) and a light subunit by SLC7A10 (GeneID: 56301),
transports glycine, L- and D-alanine, L- and D-serine, threo-
nine, and cysteine. This transport can be mediated either via
facilitated diffusion or antiport. The antiport is the predomi-
nating mechanism (Fukasawa et al., 2000). The transporter is
Na+/Cl−-independent and is found in the brain, heart, placenta,
skeletal muscle, and kidneys (Nakauchi et al., 2000). In mice, this
transporter was also identified in cells from the lungs and small
intestines (Nakauchi et al., 2000).
Other members of the SLC7 family (SLC7A1-A4) are non-
heteromeric proteins and cationic amino acid transporters
(Figure 1C). The amino acids arginine, lysine, and ornithine are
transported in a sodium-independent manner (Closs et al., 2006).
While SLC7A1 is ubiquitously expressed, the SLC7A2 transporter
(SLC7A2, GeneID: 6542) is found in skeletal muscle, placenta,
ovary, liver, pancreas, kidneys, and heart (Hoshide et al., 1996).
The SLC7A3 transporter (SLC7A3, GeneID: 84889) is expressed
in brain, thymus, uterus, testis, and mammary glands (Vekony
et al., 2001). The SLC7A4 transport protein (SLC7A4, GeneID:
6545) has no confirmed transporter activity; however, binding of
the protein to other subunits to confer transport activity has been
postulated (Wolf et al., 2002).
Peptide transporters
Four peptide transport proteins (Figure 1C) have been identi-
fied [i.e., PEPT-1 (SLC15A1, GeneID: 6564), PEPT-2 (SLC15A2,
GeneID: 6565), hPHT1 (SLC15A4, GeneID: 121260), and hPHT2
(SLC15A3, GeneID: 51296)]. PEPT-1 and PEPT-2 are well-
characterized proton symporters with overlapping substrate
specificities. These symporters transport 400 distinct di-peptides,
8000 tri-peptides, and synthetically formulated drugs (Adibi,
2003). Generally, PEPT-2 exhibits a higher affinity for di- and
tri-peptides than PEPT-1 (Shu et al., 2001; Biegel et al., 2006).
Peptide transporters are usually expressed on the apical side
of polarized cells. While PEPT-1 is highly expressed in the small
intestines, PEPT-2 is expressed in renal cells (Shu et al., 2001). All
four peptide transport proteins have been identified in the nasal
epithelium (Agu et al., 2011). Both PEPT-1 and PEPT-2 work
via secondary active transport coupled to Na+/H+ exchange,
where sodium ions are exported out of the cell via the basolat-
eral Na+/K+ ATPase pump (Leibach and Ganapathy, 1996) to
maintain the extra-cellular sodium concentration. The entire pro-
cess is supported by intra-cellular peptide hydrolyzing enzymes.
Peptides that escape hydrolysis are transported out of the cell via
an uncharacterized basolateral peptide transporter (Pieri et al.,
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Table 2 | Amino acid transport systems.
Encoding genes Encoding genes Transport Substrate Mechanism
(Gene symbols) (EntrezGene IDs) systems
SLC1A1 6505 EAAT3 Cystine, glutamic acid, aspartic acid Symport and antiport
SLC1A2 6506 EAAT2 Aspartic acid, glutamic acid Symport and antiport
SLC1A3 6507 EAAT1 Glutamic acid, aspartic acid Symport and antiport
SLC1A4 6509 ASCT1 Alanine, serine, cysteine Symport and antiport
SLC1A5 6510 ASCT2 Alanine, serine, cysteine, threonine, glutamine Antiport
SLC1A6 6511 EAAT4 Glutamate, aspartate Symport and antiport
SLC6A1 6529 GAT1 Gamma-aminobutyric acid Symport
SLC6A2 6530 NET Dopamine, norepinephrine Symport
SLC6A3 6531 DA transporter Dopamine Symport
SLC6A4 6532 SERT Serotonin Symport
SLC6A5 9152 GLYT2 Glycine Symport
SLC6A7 6534 PROT Proline Symport
SLC6A8 6535 CT1 Creatine Symport
SLC6A11 6538 GAT3 GABA Symport
SLC6A13 6540 GAT2 GABA Symport
SLC7A2 6542 CAT-2 Arginine, lysine, ornithine Uniport
SLC7A3 84889 CAT-3 Homoarginine, arginine, lysine, ornithine Uniport
SLC7A10/ SLC3A2 56301/ 6520 Asc-1/4f2hc Glycine, alanine, serine, cysteine, threonine Antiport
SLC7A11/ SLC3A2 23657/6520 XCT/4f2hc Aspartic acid, glutamic acid, cysteine Antiport
SLC16A10 117247 TATA1 Tryptophan, tyrosine, phenylalanine Uniport
SLC38A1 81539 SNAT1 Glycine, alanine, asparagine, cysteine, glutamine,
histidine, methionine
Symport
SLC38A3 10991 SNAT3 Glutamine, asparagine, histidine Symport and antiport
SLC43A2 124935 LAT4 Leucine, isoleucine, methionine, phenylalanine, valine Uniport
SLC6A6 6533 TautT Taurine, beta-alanine Symport
SLC6A14 11254 ATB0,+ All neutral and cationic amino acids Symport
SLC6A20 54716 IMINO Proline, hydroxy-proline, betaine Symport
SLC7A1 6541 Y+ (CAT-1) Lysine, arginine, ornithine, histidine Uniport
SLC7A5/ SLC3A2 8140/6520 LAT1/4f2hc Histidine, methionine, leucine, isoleucine, valine,
phenylalanine, tryptophan
Antiport
SLC7A6/ SLC3A2 9057/6520 y+LAT2/4f2hc Lysine, arginine, glutamine, histidine, methionine,
leucine
Antiport
SLC7A7/ SLC3A2 9056/6520 y+LAT1/4f2hc Lysine, arginine, glutamine, histidine, methionine,
leucine, alanine, cysteine
Antiport
SLC7A8/ SLC3A2 23428/6520 LAT2/4f2hc All neutral amino acids except proline Antiport
SLC7A9/ SLC3A1 11136/6519 b0,+AT Arginine, lysine, cystine, ornithine Antiport
SLC15A1 6564 PEPT1 Peptides Symport
SLC36A1 206358 PAT1 Glycine, proline, alanine Symport
SLC38A2 54407 SNAT2 Glycine, proline, alanine, serine, cysteine, glutamine,
asparagine, histidine, methionine
Symport
SLC38A5 92745 SNAT5 Glutamine, asparagine, histidine, alanine Symport
SLC43A1 8501 LAT3 Leucine, isoleucine, methionine, phenylalanine, valine Uniport
SLC6A15 55117 B(0)AT2 Proline, leucine, valine, isoleucine, methionine Symport
SLC6A18 348932 B(0)AT3 Glycine, alanine, methionine, serine, cysteine Symport
SLC6A19 340024 B(0)AT1 All neutral amino acids Symport
SLC7A4 6545 CAT-4 Arginine Requires additional factors for
function as amino acid transporter
SLC15A2 6565 PEPT2 Di-peptides, tri-peptides, drugs Symport
SLC36A2 153201 PAT2 Glycine, alanine, proline Symport
SLC36A4 120103 PAT4 Proline, tryptophan, alanine Facilitated diffusion
SLC38A4 55089 SNAT4 Glycine, alanine, serine, cysteine, glutamine,
asparagine, methionine
Symport
Important amino acid-derived compounds and peptides are also included. Color coding is the same as in Table 1. Details of the amino acid transport reactions in
Recon 2 are shown in Supplemental Table S1.
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2010) that can mediate either facilitative transport (Terada et al.,
1999) or proton mediated transport (Thwaites et al., 1993).
PEPT-1 is regulated by hormones and its substrates. In addi-
tion to peptides, PEPT-1 is activated by various amino acids,
including lysine, arginine, and phenylalanine. Some hormones,
such as insulin, can activate the basolateral peptide transporter,
while others, such as leptin, epidermal growth factor, and thyroid
hormone, inhibit the apical uptake of peptides by this trans-
porter (Adibi, 2003). However, PEPT-2 activity was enhanced
by minerals, such as copper, zinc, and manganese (Leibach
and Ganapathy, 1996). Interestingly, PEPT-1, when expressed in
enteroendocrine cells, is involved in hormone secretion and thus
participates in nutrient sensing (Miguel-Aliaga, 2012). In addi-
tion, increased expression of this transport protein has been asso-
ciated with various inflammatory conditions, such as ulcerative
colitis and Crohn’s disease. In contrast, PEPT-1 is not expressed
in colonocytes under normal physiological conditions (Charrier
and Merlin, 2006).
Amino acid and peptide transport systems and Recon 2
Amino acid and peptide transport systems are well described in
the literature and in Recon 2. The 667 amino acid transporter
reactions make up the largest group of extracellular transport
reactions in Recon 2, and 98% of them are supported by liter-
ature evidence (Figure 2C). Recon 2 already covered the recent
additions and modifications to the amino acid transport sys-
tems, which were identified during the reconstruction of the small
intestinal epithelial cell (Sahoo and Thiele, 2013) and the liver
(Gille et al., 2010).
Recon 2, however, still needs to be extended to account for
current knowledge (Table 2). (i) Missing transported substrates
need to be added, and our module provides the corresponding
transport reactions. For example, the renal cell specific trans-
port system SNAT4 (SLC38A4, GeneID: 55089) also transports
cysteine and methionine (Broer, 2008; Broer and Palacin, 2011).
Additionally, the transporters B(0)AT2, B(0)AT3, and PAT4 are
missing along with the transport reactions for their substrates. (ii)
GPRs for the existing transport reactions need to be expanded
(Supplemental Table S2). The function of PAT2 can be added
by expanding the GPRs of the appropriate reactions in Recon 2
(Supplemental Table S2). (iii) In the case of the PEPT-2 trans-
porter, Recon 2 correctly captures its transport of the di-peptide
Cys-Gly, but other substrates are missing, such as the tri-
peptide Trp-Trp-Trp (Leibach and Ganapathy, 1996). However,
the metabolic fate of these missing substrates is currently not cap-
tured in Recon 2; thus, the addition of the transport reactions
would create gaps. Hence, we did not include these reactions in
the transport module. For a detailed list of the endogenous and
xenobiotic substrates for PEPT-2, refer to Biegel et al. (2006).
Supplemental Table S1 is a comprehensive list of amino acid
transporters and their properties.
TRANSPORT SYSTEMS FOR LIPIDS
Lipids are essential for many biological processes. The major
dietary lipids are triacylglycerol, phospholipids, and sterols. These
dietary lipids are broken down into free fatty acids, mono-
acylglycerols, and cholesterol, which are subsequently absorbed
by cells (Gropper et al., 2009). Cholesterol and phospholipids are
essential membrane constituents. Phospholipids and glycolipids
form lung surfactants. Fat is stored within cells as triacylglycerols
and break down into glycerol and fatty acids, which are a major
source of energy for various cellular processes. Lipids also act as
precursors for second messengers. Cholesterol acts as a precursor
for steroid hormones and bile acids (Murray et al., 2009).
Due to their hydrophobic properties, the majority of lipids can
freely diffuse across the cell membrane. Nevertheless, a number of
alternative transport mechanisms exist (Figure 1D): (1) fatty acid
transport proteins, including FATP1 (SLC27A1, GeneID: 376497),
FATP2 (SLC27A2, GeneID: 11001), FATP3 (SLC27A3, GeneID:
11000), FATP4 (SLC27A4, GeneID: 10999), FATP5 (SLC27A5,
GeneID: 10998), and FATP6 (SLC27A6, GeneID: 28965); (2) the
membrane associated fatty acid transporters FABPpm (GOT2,
GeneID: 2806) and fatty acid translocase FAT (CD36, GeneID:
948); (3) ATP binding cassette transporters; (4) various lipopro-
teins (i.e., chylomicrons, very low density lipoprotein, low density
lipoprotein, and high density lipoprotein); and (5) intracellu-
lar lipid transporters, such as non-specific lipid-transfer protein
(SCP2, GeneID: 6342), acyl CoA binding protein (DBI, GeneID:
1622), fatty acid binding proteins/ cytoplasmic fatty acid binding
proteins [i.e., FABPc (FABP1-9)] (Gossett et al., 1996; Furuhashi
and Hotamisligil, 2008), and various proteins that aid in mem-
brane turnover via insertion of new lipids into pre-existing mem-
branes (i.e., flippase, floppase, scramblase, and flip-flop) (Devaux
et al., 2008; Sanyal and Menon, 2009). The presence of multiple
additional transportmechanisms besides diffusion is explained by
the essential role of lipids in the cell and the need to control their
transport and distribution. In addition, the structural differences
among fatty acids, mono-acylglycerol, and cholesterol necessitate
distinct transport systems.
Fatty acid transport
Fatty acid transport proteins (FATPs) are a family of six trans-
porters (Figure 1D) that mediate the influx of long chain fatty
acids (>10 carbons in chain length), usually associated with a
long chain fatty acid activating enzyme present on the mem-
brane (acyl-CoA synthetases, E.C. 6.2.1.3) (Jia et al., 2007). FATPs
have also been suggested to possess inherent fatty acid activat-
ing properties (Stahl, 2004), and they have an AMP-binding
motif (Glatz et al., 2010). The membrane associated fatty acid
transporters (FABPpm) also transport long chain fatty acids,
although, compared to FATPs, FABPpms have a higher affinity
toward long chain poly-unsaturated fatty acids and essential fatty
acids (Dutta-Roy, 2000). The FABPpm transport mechanism is
slightly different compared to FATP. Once transported inside the
cell by FABPpm, fatty acids bind to the cytoplasmic counter-
part (FABPc) and undergo activation (Glatz et al., 2010). The
fatty acids might then be transported to other sub-cellular com-
partments by FABPc (Stewart, 2000). The fatty acid translocase
protein (FAT, CD36, GeneID: 948) is usually expressed at low
fatty acid concentrations. FAT binds and concentrates fatty acids
at the cell surface and enhances their diffusion across the mem-
brane. Alternatively, FAT can also deliver fatty acids to FABPpm
(Glatz et al., 2010), and it has a wide substrate coverage, includ-
ing low- and high-density lipoproteins and phospholipids (Stahl
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et al., 2001; Febbraio and Silverstein, 2007). Interestingly, the indi-
vidual transport capacities (i.e., without any concertation) of FAT
and FABPpm (including FATP) have been shown in the rat skele-
tal muscles for palmitate (C16:0), and these transport proteins
also play a significant role in fatty acid oxidation (Nickerson et al.,
2009). Therefore, Chabowski et al. (2007) proposed that the need
for an association between FAT and FABPpm would arise during
conditions of increased fatty acid oxidation to meet the increased
substrate demands.
Various ABC transport proteins transport fatty acids, choles-
terol, phospholipids, and cholesterol derivatives (bile acids)
(Supplemental Table S1). ABC transporters generally conduct
primary active transport, act as ion channels for chloride, or reg-
ulate the function of ATP-sensitive potassium channels (Glavinas
et al., 2004). These transport proteins have a wide substrate spec-
trum, including drugs, lipid metabolites, hormones, heme, iron,
peptides, nucleosides, and vitamins (see Supplemental Table S1
for details on substrate specificity, associated disorders, and ref-
erences for all relevant ABC transporters). A number of the
ABC transport proteins are functional monomers, while most of
the other transport proteins require dimerization or binding to
other proteins to gain complete functionality (e.g., ABCB2/TAP1,
ABCB3/TAP2, four transporters from the ABCD sub-family, and
five transporters from the ABCG sub-family) (Glavinas et al.,
2004). The group of ATP binding cassette transporters comprises
48 transport proteins, categorized into six different families. Of
the total number of transport proteins, 32 are located on the
plasma membrane, and 13 are intracellular transport proteins
(ABCA2, ABCB2, ABCB7-10, ABCC6, ABCD1-4, ABCG1, and
ABCG4), while only three act at the plasma membrane and intra-
cellular locations. These proteins are the ATP-binding cassette
sub-family B member 6, (ABCB6, GeneID: 10058) located in the
plasma membrane, Golgi apparatus, and lysosomes; the ATP-
binding cassette sub-family A member 1, (ABCA1, GeneID: 19)
located in the plasmamembrane and the Golgi apparatus; and the
ATP-binding cassette sub-family B member 5 (ABCB5, GeneID:
340273), whose location remains to be identified (Orso et al.,
2000; Kiss et al., 2012).
Transport by lipoproteins and cholesterol transport
Lipoproteins are spherical components, containing a hydropho-
bic lipid core, amphiphilic lipids, and proteins with hydrophilic
amino acid side chains on the surface (Nelson and Cox, 2000).
Lipoproteins vary in their apolipoprotein (Apo) content, density,
and lipid components. Chylomicrons are the largest lipoproteins,
have the least density (i.e., <1.006 g/ml), and carry the high-
est fraction of triacylglycerols (Nelson and Cox, 2000). They
are formed in the endoplasmic reticulum of small intestine cells
and carry the lipid components of the diet into the lymph
where they enter the blood via the left subclavian vein (Nelson
and Cox, 2000). When passing through the blood capillaries,
lipoprotein lipase (LPL, GeneID: 4023, E.C. 3.1.1.34) extracts
the free fatty acids and releases them into muscle and adipose
tissues. The liver takes up the remnant chylomicrons, where
the excess fatty acids may be used to synthesize triacylglycerols,
which are further transported into tissues as part of very low-
density lipoprotein (VLDL). After removing the triglycerides,
the unused VLDL or VLDL remnants, which are intermediate-
density lipoproteins, are then either reabsorbed into the liver
or form low-density lipoprotein (LDL). The small intestine and
liver also form precursors for high-density lipoprotein (HDL) and
release them into the circulation. HDL transport is also called
reverse cholesterol transport. The major components transported
by the four lipoprotein classes (Figure 1D) are (i) triacylglyc-
erol by chylomicrons, (ii) phospholipids and triacylglycerol by
VLDL, (iii, iv) cholesteryl esters and phospholipids by LDL and
HDL (Nelson and Cox, 2000). In addition, all fat-soluble vita-
mins (vitamin A, D, E, and K) are also transported within
chylomicrons, passing from the intestinal epithelial cells into
the lymph (Reboul and Borel, 2011). The cellular uptake of
cholesterol is also mediated by Niemann-Pick C1-like protein 1
(NPC1L1, GeneID: 29881) and SRB-I (SCARB1, GeneID: 949),
where the latter takes up cholesterol from HDL (Ikonen, 2008;
Reboul and Borel, 2011). In contrast, in the case of polarized
cells, luminal efflux occurs through the ATP-binding cassette
sub-family G member 5/ ATP-binding cassette sub-family G
member 8 ABCG5/ABCG8 (ABCG5, ABCG8, GeneID: 64240 &
64241), and basolateral efflux is mediated by the ATP-binding
cassette sub-family A member 1 ABCA1 (ABCA1, GeneID: 19)
(Ikonen, 2008). The substrate specificities of these proteins have
not been entirely resolved, and the exact transport mechanism
needs further experimental support. According to the current
understanding, NPC1L1 is a uniport and is recycled through an
endocytic route (Reboul and Borel, 2011). Bi-directional trans-
port has been indicated for SRB-I (Ikonen, 2008; Reboul and
Borel, 2011). Still, for the majority of lipid transporters (includ-
ing for fat-soluble vitamins), the precise transport mechanism
with respect to directionality, coupled ions or other compounds,
and substrate stoichiometry remain uncertain (Reboul and Borel,
2011).
Lipid transport systems and Recon 2
In Recon 2, the majority of reactions associated with lipid
transport were simple diffusion reactions (91 of 183 reactions,
Figure 2D), and 11% of the reactions were not supported by
literature evidence (Figure 2C). The substrate coverage of the
existing FATPs was increased in Recon 2 with the addition of
long chain fatty acid transport reactions (Table 3). However,
FAT (CD36, GeneID: 948) and FABPpm (GOT2, GeneID: 2806)
are still missing in Recon 2 and are captured in the transport
module.
Of all of the ABC transport proteins located at the plasma
membrane, only seven transporters were captured in Recon 2.
Moreover, the transport for a number of substrates is missing,
which includes poly-unsaturated fatty acids, xenobiotics, nucle-
osides, nucleotides, and ions (see Supplemental Table S1 for a
complete list). The transport module accounts for the missing
transporters (ABCA3, ABCA4, ABCA8, ABCC11, and ABCG2).
In addition, the transport module expands the substrate cover-
age for the ABCA1 transporter with phosphatidyl-choline and
phosphatidyl-serine. Furthermore, the cholesterol transport pro-
teins ABCG5 and ABCG8 are missing in Recon 2, and these pro-
teins were added by expanding the GPRs for the corresponding
reactions in Recon 2 (Supplemental Table S2).
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Table 3 | Lipid and vitamin transporters.
Encoding genes Encoding genes Transporters Substrate
(Gene symbols) (EntrezGene IDs)
LIPID TRANSPORTERS
ABCA1 19 ATP-binding cassette sub-family A
member 1
Cholesterol
SLC27A1
376497 FATP-1 Broad specificity for both long and very long chain fatty
acids, C18:1, C20:4, C16:0, C24:0
SLC27A2 11001 FATP-2 C16:0, C24:0, bile acids
(3α,7α,12α-trihydroxy-5β-cholestanoic acid,
3α,7α-dihydroxy-5β-cholestanoic acid), other long chain
fatty acids
SLC27A3 11000 FATP-3 Long chain fatty acids
SLC27A4 10999 FATP-4 Long chain fatty acids, C18:1, C20:4
SLC27A5 10998 FATP-5 Long chain fatty acids
SLC27A6 28965 FATP-6 Long chain fatty acids, C16:0, C18:0 (not active for
chain length shorter than C10)
ABCG5
64240 ATP-binding cassette sub-family G
member 5
Cholesterol
ABCG8 64241 ATP-binding cassette sub-family G
member 8
Cholesterol
CD36 948 FAT Very long chain fatty acids, HDL, VLDL, LDL,
phospholipids, advanced glycation end products, GHRP,
hexarelin, and a derivative with no growth hormone
releasing properties, EP 80317, vitamin D
GOT2 2806 FABPpm Long chain fatty acids
NPC1L1 29881 Niemann-Pick C1-like protein 1 Cholesterol, cholestanol, campesterol, sitosterol,
vitamin E, vitamin D
SCARB1 949 Scavenger receptor class B,
member 1
HDL-cholesterol
VITAMIN TRANSPORTERS
SLC5A6 8884 SMVT Pantothenic acid, biotin
SLC19A1 6573 RFT / Reduced folate carrier (RFC) 5-methyl THF, thiamin-mono- and di-phosphates, but
not free thiamin
SLC19A2 10560 ThTr1 Thiamin, thiamin-mono- and di-phosphate
SLC19A3 80704 ThTr2 Thiamin, thiamin-mono- and di-phosphate
CUBN
8029 Vitamin D transporters Vitamin D
FOLR1, FOLR3, FOLR2 2348, 2352, 2350 Folate receptor (FOLR1, FOLR3) 5-Methyltetrahydrofolate
GIF, CUBN, AMN 2694, 8029, 81693 Cobalamin transporters B12 (cobalamin)
SLC23A1 9963 SVCT1 L-ascorbic acid
SLC23A2 9962 SVCT2 L-ascorbic acid
SLC46A1 113235 PCFT Heme, folate
SLC52A1 55065 RFT1 Riboflavin
SLC52A3 113278 RFT2 Riboflavin
GC, LRP2 2638, 4036 Vitamin D transporters Vitamin D
OATP-2 (SLCO1B1),
OATP-1 (SLCO1A2),
OAT1 (SLC22A6), OAT3
(SLC22A8), OAT2
(SLC22A7), OAT4
(SLC22A11)
10599, 6579, 9356,
9376, 10864, 55867
Folate transporters Folate
RBP4, STRA6, RBP1,
RBP2
5950, 64220, 5947, 5948 Vitamin A transporters Retinol
SCARB1, NPC1L1,
ABCA1
949, 29881, 19 Vitamin E transporters Vitamin E
SLC5A8 160728 SMCT1 Iodide, lactate, short-chain fatty acids, niacin
SLC52A2 79581 RFT3 Riboflavin
The color coding is the same as in Table 1. Details of the lipid and vitamin transport reactions in Recon 2 are shown in Supplemental Table S1.
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TRANSPORT SYSTEM FOR NUCLEOSIDES
The liver is the major organ for the de novo synthesis of all four
nucleosides (Fustin et al., 2012). Another source of nucleic acids
is ingestion and digestion. Nucleosides and nucleic acid bases
are transported across biological membranes by concentrative
nucleoside transporters (CNT) (Marce et al., 2006), equilibrative
nucleoside transporters (ENT) (Marce et al., 2006), and trans-
porters of the ABC transport family (Toyoda and Ishikawa, 2010;
Fukuda and Schuetz, 2012).
Three CNTs exist (Figure 1E), each with distinct substrate
specificity: CNT1 (SLC28A1, GeneID: 9154) shows a high affin-
ity for pyrimidine nucleosides (e.g., cytidine, thymidine), CNT2
(SLC28A2, GeneID: 9153) prefers purine nucleosides (e.g., adeno-
sine, guanosine), and CNT3 (SLC28A3, GeneID: 64078) exhibits
a wide substrate specificity (Marce et al., 2006; Pastor-Anglada
et al., 2007). CNTs mediate sodium-coupled secondary active
symport. Recent findings have revealed the coupling of CNT3
with Na+ or H+ (Molina-Arcas et al., 2008). The four exist-
ing ENTs belong to the SLC29A gene family and exhibit a
wide substrate specificity (Marce et al., 2006; Pastor-Anglada
et al., 2007), including nucleic acid bases. ENT1-ENT3 medi-
ate facilitated diffusion or uniport in a sodium-independent
manner. ENT4 (SLC29A4, GeneID: 222962) works via a sec-
ondary active transport coupled to H+ (Molina-Arcas et al.,
2008). In the case of enterocytes and renal cells, the CNTs are
located at the apical surface, mediating the uptake of nucle-
osides, while ENTs mediate influx and efflux on the basolat-
eral side (Pastor-Anglada et al., 2007). Both CNTs and ENTs
transport a wide range of pharmacologically important drugs
(Molina-Arcas et al., 2008). The transporters of the ABC trans-
port family that transport nucleotides and nucleosides are mul-
tidrug resistance-associated protein 4 (ABCC4, GeneID: 10257),
multidrug resistance-associated protein 5 (ABCC5, GeneID:
10057), ATP-binding cassette sub-family C member 11 (ABCC11,
GeneID: 85320), and ATP-binding cassette sub-family G member
2 (ABCG2, GeneID: 9429) (Toyoda and Ishikawa, 2010; Fukuda
and Schuetz, 2012). See Supplemental Table S1 for details on
substrate specificity and associated properties.
Nucleoside transporters and Recon 2
Nucleoside transport is well established. Accordingly, 88% of
the nucleoside transport reactions in Recon 2 are supported
by literature evidence (Figure 2C). While only the reactions
for the CNTs and ENT1-ENT3 are present in Recon 2, ENT4
(SLC29A4, GeneID: 222962) (Baldwin et al., 2004) was added
to the transport module. Transport via CNT3 is associated with
Na+ or H+ gradients (Molina-Arcas et al., 2008). However, only
Na+-coupled secondary active transport was captured in Recon
2 (Supplemental Table S1). The CNT3-mediated, H+-coupled
transport is covered in the transport module. In addition, gene
information for the ABC transport proteins [i.e., ATP-binding
cassette sub-family C member 11 (ABCC11, GeneID: 85320) and
ATP-binding cassette sub-family G member 2 (ABCG2, GeneID:
9429)] needs to be added to the corresponding Recon 2 reac-
tions (Supplemental Table S2). Another useful, future addition
with respect to disease-directed research and the application of
human GENREs could be the transport of nucleotide-derived
drugs. Refer to (Molina-Arcas et al., 2008) for a list of drugs that
are transported by these transporters.
TRANSPORT SYSTEM FOR VITAMINS
Vitamins are not synthesized by the human body and are there-
fore essential components of the human diet. Some vitamins,
such as biotin, are also synthesized by the commensal gut
microflora (Murray et al., 2009). Niacin can be synthesized in
the body from the amino acid tryptophan (Murray et al., 2009).
Vitamins have traditionally been divided into two groups: (1)
fat-soluble vitamins comprising vitamins A, D, E, and K, and
(2) water-soluble vitamins comprising the B complex of thi-
amin (B1), riboflavin (B2), niacin (B3), pyridoxal (B6), folic acid,
cobalamin (B12), pantothenic acid, and biotin, and vitamin C.
Vitamins play a major role in a variety of biochemical processes.
Vitamin A is involved in the visual cycle, vitamin D in calcium
metabolism, vitamin E in free radical scavenging, vitamin K in
blood clotting, B1 in carbohydrate metabolism and nerve con-
duction, B2 and B3 in redox reactions, B6 in transamination
reactions, folic acid and cobalamin in one carbon metabolism,
pantothenic acid in fatty acid metabolism, biotin in carboxylation
reactions and vitamin C in hydroxylation reactions (Murray et al.,
2009). The body’s inability to synthesize vitamins and their piv-
otal role in metabolic processes necessitate transport mechanisms
other than simple diffusion for their import into a particular cell
type and efflux for utilization by other cell types. Epithelial cells in
the small intestine, kidneys, and liver express the vast majority of
ABC and SLC transporters because these organs play a chief role
in the absorption and secretion of endogenous metabolites and
xenobiotics (Brunton et al., 2006; Klaassen and Aleksunes, 2010).
Epithelial cells are among the best models to study transport pro-
cesses. Hence, we will focus on the transport proteins present in
the enterocytes of the small intestine.
TRANSPORT OF FAT-SOLUBLE VITAMINS (FSVs)
FSVs were believed to enter enterocytes from the intestinal lumen
via passive diffusion. However, transport proteins for vitamins A,
D, and E have been identified, and energy-dependent transport
has been suggested for vitamin K in rats (Hollander et al., 1977).
Vitamin A is transported in the plasma bound to retinol
binding protein. Its uptake into enterocytes is mediated by
retinoic acid gene 6 protein homolog (STRA6) protein (STRA6,
GeneID: 64220) (Berry et al., 2011). A transporter of ABC family
[i.e., retinal-specific ATP-binding cassette transporter (ABCA4,
GeneID: 24)], is involved in the transport of retinaldehyde, a
form of vitamin A, into retinal photoreceptors (Burke and Tsang,
2011). Retinol-binding protein 1 (RBP1, GeneID: 5947) and
retinol-binding protein 2 (RBP2, GeneID: 5948) aid in apical
uptake, esterification, and secretion of retinol (Harrison, 2005).
So far, no basolateral transport protein for vitamin A has been
identified (Reboul and Borel, 2011). The basolateral efflux of
retinol (in the form of retinyl-esters) has been assumed to pri-
marily occur via chylomicrons.
Vitamin D is mainly transported in the circulation bound
to vitamin D-binding protein, which has a higher affinity for
25-hydroxy vitamin D than for vitamin D3 (Ball, 2006). Once
bound, the complex is recruited by megalin (LRP2, GeneID:
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4036) and cubilin (CUBN, GeneID: 8029) either for hydroxyla-
tion or efflux (Dusso et al., 2005). In addition, SR-BI (SCARB1,
GeneID: 949), FAT (CD36, GeneID: 948) and NPC1L1 (NPC1L1,
GeneID: 29881) are involved in the intestinal uptake of vitamin D
(Reboul et al., 2011). The SR-BI protein has been shown to play a
role in the apical uptake and basolateral efflux of vitamins D and
E in caco-2 cells (Reboul and Borel, 2011). Moreover, vitamin D
is transported within chylomicrons into the lymph (Ball, 2006).
Vitamin E uptake appears to be similar to that for choles-
terol. Although passive diffusion has been observed, additional
receptor-mediated transport is through SRB-I and NPC1L1
(Reboul et al., 2006; Narushima et al., 2008). Basolateral efflux
occurs via the ABC family protein ABCA1 (ABCA1, GeneID: 19)
(Rigotti, 2007).
TRANSPORT OF WATER-SOLUBLE VITAMINS
Both the low concentration and hydrophilicity of water-soluble
vitamins make simple diffusion highly inefficient. Distinctive
carrier-dependent transporters exist at the apical and basolateral
sides of enterocytes to mediate vitamin exchange (Figure 1F).
Vitamin B1
Three transport proteins are associated with the transport of vita-
min B1, and its structural analogs [i.e., ThTr1 (SLC19A2, GeneID:
10560), ThTr2 (SLC19A3, GeneID: 80704), and RFT (SLC19A1,
GeneID: 6573)]. While ThTr1 and ThTr2 can transport free thi-
amin, RFT transports the mono- and di-phosphate forms of
thiamin (Zempleni et al., 2007; Said, 2011). Sub-cellular loca-
tions vary between the transporters. ThTr1 is located at the apical
and basolateral membranes. In contrast, ThTr2 and RFT are local-
ized only to the basolateral membrane. The transport of vitamin
B1 occurs against concentration and an outwardly directed H+
gradient and appears to be sodium-independent, electroneutral,
and pH-dependent (Said, 2004). However, the directionality or
reversibility of these transport processes remains to be elucidated.
Vitamin B2
The uptake and secretion of vitamin B2 from enterocytes
involves primary active transport (Said et al., 1993; Bates,
1997; Subramanian et al., 2011) mediated by three transport
proteins, RFT1 (SLC52A1, GeneID: 55065), RFT2 (SLC52A3,
GeneID: 113278), and RFT3 (SLC52A2, GeneID: 79581). RFT1
is expressed at the basolateral membrane and RFT2 at the apical
membrane, leading to vitamin B2 efflux and uptake, respectively
(Subramanian et al., 2011). Both transporters are expressed in the
small intestine (Yao et al., 2010). RFT3 is specifically expressed in
the brain (Yao et al., 2010).
Vitamin B3
The cellular uptake of niacin (also called vitamin B3 or nico-
tinic acid) can occur by simple diffusion (Ball, 2006). In addition,
niacin is taken up via sodium-independent and temperature-
and acidic pH-dependent facilitated diffusion (Nabokina et al.,
2005). No specific carrier protein has so far been identified for
vitamin B3. Yet, SMCT1 (SLC5A8, GeneID: 160728), principally
an iodide transporter, has been suggested to mediate sodium-
coupled niacin transport (Gopal et al., 2007). The mechanism for
the basolateral efflux of niacin and the carrier protein involved is
unknown (Said, 2011).
Vitamin B6
Vitamin B6 diffuses freely across the cell membrane (Ball, 2006).
However, carrier-dependent transport (sodium-independent but
pH-, energy-, and temperature-dependent) has also been sug-
gested (Said et al., 2003). No specific transport protein has been
characterized at the molecular level.
Folate (vitamin B9)
Folate plays a role in various biochemical processes (e.g., DNA
synthesis, one carbon metabolism, and amino acid metabolism),
in the prevention of congenital abnormalities (e.g., neural
tube defects, urogenital abnormalities, cardiovascular malforma-
tions, cleft lip, and palate) and the prevention and treatment
of cardiovascular diseases (Tolarova, 1982; Czeizel and Dudas,
1992; Czeizel, 1996; Tian and Ingwall, 2008). Given its general
importance, not surprisingly, multiple folate transporters exist.
Traditionally, the two folate carriers are the reduced folate carrier
(SLC19A1, GeneID: 6573) and proton-coupled folate transporter
(SLC46A1, GeneID: 113235). In addition, three high-affinity
folate receptors, a number of ABC transporters, and members
of the solute carrier organic anion transporter family have been
associated with the transport of folate or its derivatives. They will
be discussed in the following paragraphs.
The reduced folate carrier is an organic anion antiporter that
utilizes a high trans-membrane organic phosphate gradient. This
carrier is expressed at the distal part of the small intestine and
operates at neutral pH (Said, 2011). The proton-coupled folate
transporter mediates the transport of folic acid and 5-methyl- and
formyl-tetrahydrofolates. The transporter localizes to the proxi-
mal small intestine, operates at an acidic pH (Said, 2011; Zhao
et al., 2011), and has been shown to also transport heme (Zhao
et al., 2011).
The three high-affinity folate receptors are FRα (FOLR1,
GeneID: 2348), FRβ (FOLR2, GeneID: 2350), and FRγ (FOLR3,
GeneID: 2352). They mediate the unidirectional influx of folate,
whereby the entire folate-receptor complex is internalized (Ball,
2006; Zhao et al., 2011). A reversible transport has also been
suggested (Zempleni et al., 2007).
The basolateral folate transporter has not yet been character-
ized at themolecular level. However, the presence of a specific car-
rier protein mediating sodium-independent but pH-dependent
folic acid transport has been shown in rats (Hamid et al., 2009). In
the case of humans, 5-methyl-tetrahydrofolate has been identified
in the portal blood (Ball, 2006), but the corresponding transport
mechanisms and proteins have not been elucidated.
Seven ABC transporters expressed in the plasma membrane
in different epithelial and non-epithelial cells have shown affin-
ity toward folate and its derivatives (Matherly and Goldman,
2003; Toyoda and Ishikawa, 2010; Zhao et al., 2011). Multidrug
resistance-associated protein 1 (ABCC1, GeneID: 4363) and mul-
tidrug resistance-associated protein 5 (ABCC5, GeneID: 10057)
are expressed on the basolateral side, and the canalicular mul-
tispecific organic anion transporter 1 (ABCC2, GeneID: 1244)
is present on apical side of enterocytes. ABCC5 and ABCC2 are
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further expressed on the basolateral side of hepatocytes. The
remaining four ABC transporters are ATP-binding cassette sub-
family G member 2 (ABCG2, GeneID: 9429), multidrug resis-
tance protein 3 (ABCB4, GeneID: 5244), ATP-binding cassette
sub-family C member 11 (ABCC11, GeneID: 85320), and mul-
tidrug resistance-associated protein 4 (ABCC4, GeneID: 10257).
Numerous solute carrier organic anion transporters (OAT)
transport methotrexate (a structural analog of folic acid) and
are also relevant folate transporters in the liver and kidneys
(Matherly and Goldman, 2003; Zhao and Goldman, 2003). These
transporters include OATP-2 (SLCO1B1, GeneID: 10599) in the
liver (basolateral side) and OATP-1 (SLCO1A2, GeneID: 6579),
OAT1 (SLC22A6, GeneID: 9356), OAT3 (SLC22A8, GeneID:
9376), OAT2 (SLC22A7, GeneID: 10864), and OAT4 (SLC22A11,
GeneID: 55867) in the kidneys (Takeda et al., 2002; Badagnani
et al., 2006; Zhao et al., 2011). One can refer to (Zhao et al.,
2011) for the precise apical/basolateral localizations of these folate
transporters.
Vitamin B12
Vitamin B12 is the precursor for two coenzymes, adenosylcobal-
amin and methylcobalamin. Adenosylcobalamin is required for
methylmalonyl CoA-mutase activity (E.C. 5.4.99.2), which cat-
alyzes the conversion of methyl malonyl-CoA to succinyl-CoA.
Methylcobalamin is required for methionine synthase activity
(E.C. 2.1.1.13), which catalyzes the methylation of homocysteine
to methionine (Murray et al., 2009; Watkins and Rosenblatt,
2011). The absorption of cobalamin by simple diffusion along
the entire small intestine accounts for 1–3% of dietary vitamin
B12. Interestingly, this vitamin depends on a carrier-mediated
transport when administered in pharmacological doses (Ball,
2006).
Cobalamin is transported into intestinal epithelial cells by
cubilin-mediated absorption. The vitamin binds to intrinsic fac-
tor (GIF, GeneID: 2694), building the intrinsic factor-cobalamin
complex (IF-Cbl) and to two proteins called cubilin (CUBN,
GeneID: 8029) and amnionless (AMN, GeneID: 81693). The lat-
ter serve as an anchor for the receptor and aids cobalamin uptake.
In addition, proteins, such as megalin and receptor-associated
protein, can interact with CUBN. Whether the binding of addi-
tional proteins plays a role in the CUBN-mediated absorption
of IF-Cbl has not been determined (Quadros, 2010). The pro-
tein responsible for the basolateral efflux of cobalamin has not
been experimentally validated. However, multidrug resistance-
associated protein 1 (ABCC1, GeneID: 4363) has been shown
to transport cobalamin in prokaryotes and eukaryotes, including
mice (Green, 2010).
Pantothenic acid and biotin
Pantothenic acid and biotin are absorbed at the apical mem-
brane by a common sodium coupled symporter, SMVT (SLC5A6,
GeneID: 8884) (Ball, 2006). In addition, SMVT transports lipoic
acid and is called a multi-vitamin transporter. The basolateral
release of biotin is mediated by a yet uncharacterized carrier pro-
tein in a sodium-independent manner (Said, 1999). The mecha-
nism of basolateral pantothenate efflux remains to be elucidated
(Said, 2011).
Vitamin C
Two transport proteins, the apically located SVCT1 (SLC23A1,
GeneID: 9963) and the basolaterally located SVCT2 (SLC23A2,
GeneID: 9962), mediate vitamin C (also called ascorbate or
L-ascorbic acid) uptake. The membrane location has been con-
firmed in rats (Boyer et al., 2005). SVCT2 is ubiquitously
expressed (except in the lungs and skeletal muscle), whereas
SVCT1 is confined to the intestines, liver, kidneys, colon, ovaries,
and prostrate (Liang et al., 2001). Both transport proteins
exhibit Na+-coupled secondary active symport (coupling ratio
2:1) (Liang et al., 2001), energized by Na+/K+ ATPase (Ball,
2006). Ascorbate export has been assumed via volume-sensitive
anion channels (Wilson, 2005). Alternatively, intracellular vita-
min C can be oxidized to dehydroascorbate, which can freely
diffuse into the blood stream (Gropper et al., 2009). Three trans-
porters in the GLUT family (GLUT-1, GLUT-3, and GLUT-4)
also mediate the uptake of dehydroascorbate on the basolateral
side (Wilson, 2005). In astrocytes, GLUT-1 facilitates entry, and
GLUT-3mediates the efflux of dehydroascorbate (Hediger, 2002).
Vitamin transporters and Recon 2
Transport systems for water-soluble vitamins have been more
intensively investigated than FSVs (Reboul and Borel, 2011). FSV
transport was not well represented in Recon 2, but the trans-
port of water-soluble vitamins was fairly well captured. Overall,
74% of the vitamin transport reactions are supported by literature
evidence (Figure 2C). However, the genes encoding for proteins
transporting fat-soluble vitamins, including those discussed for
vitamins A, D, and E (i.e., STRA6, ABCA4, RBP1, RBP2, LRP2,
CUBN, SR-BI, and NPC1L1), are absent in Recon 2. The trans-
port protein encoded by the ABCA1 gene is so far only associated
with cholesterol, but not vitamin E transport (Table 3). The trans-
port module accounts for vitamin A transport by ABCA4, while
the other missing genes have been added by expanding the GPRs
of the respective transport reactions (Supplemental Table S2).
Recon 2 includes the vitamin B2 transporters, RFT1 and 2,
but not RTF3, which can be added by expanding the corre-
sponding GPRs (Supplemental Table S2). Recon 2 also accounts
for the substrate specificity of PCFT, FOLR1, and FOLR3. The
transport of folate by FOLR2, and of vitamin B3 by SMCT1
can be accounted for by expanding the GPR of the correspond-
ing reaction. OAT1—OAT4-mediated transport can be added,
via the module, to completely capture the current knowledge
about folate transporters. The vitamin B12 transport proteins
(i.e., intrinsic factor, cubilin, and amnionless) and the ATP costs
of SVCT1/SVCT2 transport are already accounted for in Recon 2.
See Supplemental Table S1 for the vitamin transporters and their
properties.
TRANSPORT OF WATER, HEME, AND OTHER SPECIAL COMPOUNDS
Water moves across biological membranes via different
mechanisms. Apart from diffusing through the lipid bilayer,
co-transporters in the form of protein channels exist in the mem-
brane, through which water can diffuse. The movement of water
molecules through such channels, called aquaporins, is driven by
osmosis (Macaulay et al., 2004). Water is also a substrate for co-
transporters, such as excitatory amino acid transporter 1 EAAT1
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(SLC1A3, GeneID: 6507), which is expressed in the brain and
moves both urea and water along with glutamate (Vandenberg
et al., 2011), and for the sodium glucose co-transporter, SGLT1,
which transports sodium and glucose, while causing water
influx (Zeuthen et al., 2001). For details on the various water
co-transporters, specifically those operating in the brain, one
may refer to (Macaulay et al., 2004).
Aquaporins
Aquaporins are a family of membrane channel proteins that allow
the passage of water molecules, neutral molecules (e.g., urea and
glycerol) and other small solutes (Zardoya and Villalba, 2001). In
total, 13 members of this family have been characterized at the
molecular level, and they are expressed in a wide variety of tis-
sues (abundantly in the epithelial layer of the kidneys, intestine,
lungs, and brain) (Verkman, 2005). While a majority of these
proteins are expressed on the plasma membrane, aquaporin-6
(AQP6, GeneID: 363) and aquaporin-2 (AQP2, GeneID: 359) are
also localized to intracellular vesicles (Yasui et al., 1999; Verkman,
2012). Interestingly, these proteins have been associated with var-
ious cellular functions, including skin hydration (Dumas et al.,
2007), neural signal transduction (Amiry-Moghaddam et al.,
2003; Yang et al., 2013), and cell volume regulation (Hansen
and Galtung, 2007). Aquaporins are believed to hold therapeu-
tic potential for congestive heart failure, hypertension, glaucoma,
brain swelling, epilepsy, obesity, and cancer (Verkman, 2005,
2012; Tradtrantip et al., 2009).
Heme
Heme forms the prosthetic group of hemoglobin and other
heme-containing proteins, such asmyoglobin, cytochromes P450,
cytochrome C, tryptophan pyrrolase, and catalase (Murray et al.,
2009). In addition, heme degradation serves as a source for the
essential micronutrient iron (Iannotti et al., 2006). Two transport
proteins have been identified for heme (Figure 1G), the proton-
coupled folate transporter (SLC46A1, GeneID: 113235, discussed
above) and the feline leukemia virus subgroup C receptor-
related protein 1 (FLVCR1, GeneID: 28982). These transport
proteins directly transfer extracellular heme into the cell. While
the proton-coupled folate transporter acts at the apical surface,
the feline leukemia virus subgroup C receptor-related protein 1
is believed to have an active transport mechanism (Uc et al.,
2004) and is localized to the basolateral surface of polarized
cells (West and Oates, 2008). The hemopexin protein directly
interacts with feline leukemia virus subgroup C receptor-related
protein 1, hence increasing heme efflux, which is perceived to
be a cellular protection against heme toxicity (Yang et al., 2010).
Heme transport can also occur via receptor-mediated endocy-
tosis, by prolow-density lipoprotein receptor-related protein 1
(LRP1, GeneID: 4035), which has been proposed to play a role in
inflammation (Hvidberg et al., 2005). The ABC transporter ATP-
binding cassette sub-family G member 2 (ABCG2, GeneID: 9429)
can also transport heme (Krishnamurthy et al., 2004).
TRANSPORT OF CONDITIONALLY ESSENTIAL NUTRIENTS
In addition to essential nutrients, there are certain other condi-
tionally essential nutrients (CEN), which are usually synthesized
by the body in almost sufficient amounts. However, under con-
ditions of increased need, such as tissue injury or neonatal con-
ditions, these nutrients may need to be derived from the diet.
CEN includes compounds, such as arginine, CoQ10, carnitine,
propionyl carnitine, taurine, lipoic acid, betaine, ribose, cysteine,
chondroitin sulfate, and glutamine (Kendler, 2006; Soghier and
Brion, 2006). In this section, we will focus only on carnitine,
taurine and betaine because the transport of arginine, cysteine,
glutamine, and ribose has already been discussed in the relevant
sections above (also see Supplemental Table S1).
Carnitine
Carnitine transports fatty acyl-CoAs (i.e., activated fatty acids)
into mitochondria, via the carnitine shuttle system (Murray
et al., 2009) (Figure 1G). A positive effect of carnitine sup-
plementation has been demonstrated for neuro-regeneration
in rats (McKay Hart et al., 2002), liver cirrhosis in children
(Selimoglu et al., 2001), obesity and associated metabolic disor-
ders (Amin and Nagy, 2009), congestive heart failure (Kobayashi
et al., 1992), and various other diseases, which are reviewed in
Flanagan et al. (2010). Carnitine further exerts protective effects
in corneal epithelial cells preventing the deleterious effects of
dry eye syndrome (Xu et al., 2010). While carnitine synthe-
sis occurs using methionine and lysine in the liver and kidney
(Flanagan et al., 2010), exogenous carnitine needs transporters
to reach the target cells. There are two membrane transport pro-
teins for this purpose, OCTN1 (SLC22A4, GeneID: 6583) and
OCTN2 (SLC22A5, GeneID: 6584). OCTN1 transports organic
cations and carnitine (in zwitter ion form) in a pH-dependent
and sodium-independent manner, chiefly behaving as a pro-
ton/organic cation antiporter at the apical surface of polarized
cells (Yabuuchi et al., 1999). OCTN2 is a sodium-dependent car-
nitine transporter that is also localized on the apical membrane
and mediates organic cation/carnitine exchange (Ohashi et al.,
2001). Additional carnitine transport proteins are the amino
acid transporter ATB0,+ (SLC6A14, GeneID: 11254), which we
discussed above (Hatanaka et al., 2004), and CT2 (SLC22A16,
GeneID: 85413), which is exclusively found in the testis and func-
tions in a sodium-independent manner (Enomoto et al., 2002).
ATB0,+ operates when OCNT2 is defective (Srinivas et al., 2007).
Taurine
One of the end products of methionine and cysteine metabolism
is taurine, which plays an important role in a number of
tissues. In the brain, taurine acts as a neuromodulator, neu-
rotransmitter, and membrane stabilizer (Tamai et al., 1995).
High taurine concentrations in the heart and muscles sup-
port its contractile function and osmo-regulation, and taurine
can also exert antioxidant action by neutralizing hypochlorous
acid and regulating mitochondrial protein synthesis in these
tissues (Schaffer et al., 2010). Additional evidence for the impor-
tance of this amino acid in human health suggests its positive
effect on growth in low birth weight infants, promotion of bil-
iary flow, and prevention of cholestasis (Guertin et al., 1991;
Stapleton et al., 1997). Disruption of taurine transport causes
retinal degeneration in mice (Heller-Stilb et al., 2002). Two
taurine transporter exist (Figure 1G), TAUT (SLC6A6, GeneID:
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6533) and PAT1 (SLC36A1, GeneID: 206358). TAUT (SLC6A6,
GeneID: 6533) mediates sodium and chloride ion-coupled sec-
ondary active transport. The stoichiometry is 1 taurine: 2
sodium: 1 chloride, but limited transport activity has also been
observed without chloride (Tamai et al., 1995). Although the
transport directionality remains to be confirmed, the move-
ment of taurine through the blood-brain barrier was shown to
occur from the blood into the brain (Tamai et al., 1995). The
second taurine transporter PAT1 (SLC36A1, GeneID: 206358)
operates via H+/taurine symport. This high-capacity but low-
affinity transporter, which also transports beta-alanine, is highly
expressed on the apical membrane of enterocytes (Anderson et al.,
2009).
Betaine
Betaine is another important molecule involved in methionine
metabolism. Once synthesized from choline, betaine donates its
methyl group to regenerate methionine from homocysteine and
helps to conserve the cellular methionine level (Craig, 2004).
In addition, betaine acts as an osmolyte, particularly help-
ful for normal physiological functions of the kidneys, intesti-
nal epithelium, red blood cells, and skeletal muscle. Moreover,
its protective role has been observed in the heart and liver
cells (Craig, 2004). Na+/Cl−-dependent secondary active betaine
transport (Figure 1G) is mediated by BGT-1 (SLC6A12, GeneID:
6539) (Yamauchi et al., 1992). Another study reported Na+-
independent, passive transport in rats (Craig, 2004). An alter-
nate substrate of BGT-1 is gamma-amino-butyric acid (see
Supplemental Table S1). Details regarding the directionality of
BGT-1-mediated transport remain unknown. The amino acid
transporter imino (SLC6A20, GeneID: 54716) also transports
betaine (Broer, 2008).
Transport of water, heme and other special compounds in Recon 2
Recon 2 contain aquaporin-8 (AQP8, GeneID: 343) and
aquaporin-9 (AQP9, GeneID: 366) for the transport of water,
urea, and lactate. Extracellular water transport also occurs
in Recon 2 through simple diffusion (“H2Ot”) and co-
transport via SGLT-1 (“UREAt5”). The other aquaporins (AQP0,
AQP1- AQP5, AQP7, and AQP10) need to be added (see
Supplemental Table S1 for details on water transporters and their
associated properties). The transport module adds reactions and
genes for AQP3, AQP7, and AQP10. The remainder of the aqua-
porins can be accounted for by expanding the GPRs of the cor-
responding reactions (Supplemental Table S2). Recon 2 lacks the
heme transporter FLVCR1 because additional biochemical exper-
iments needed to clarify the precise transport mechanism. LRP1
can be added by GPR modification (Supplemental Table S2). All
of the above discussed carnitine transport proteins, except for
CT2, are present in Recon 2. The function of CT2 is captured in
the transport module. In addition, carnitine transport mediated
by the amino acid transporter ATB0,+ is missing in Recon 2 but
can be accounted for through the transport module. Efficient tau-
rine transport, via TAUT, coupled to Na+ and Cl− ions, is present
in Recon 2. The transport reactions catalyzed by BGT-1 [i.e.,
“ABUTt4(2)r” for betaine and “GLYBt4(2)r” for GABA] need to
be corrected for the requirement of both sodium and chloride
ions. Therefore, the transport module contains the improved
reactions for the ATB0,+ and BGT-1 transporters.
TRANSPORT REACTION MODULE
The transport module was assembled according to the estab-
lished reconstruction protocol (Thiele and Palsson, 2010a) using
rBioNet as a reconstruction tool (Thorleifsson and Thiele, 2011).
The functionality of reactions in the module, in conjunction
with Recon 2, was subsequently tested. All of the discussed
modifications and additions are provided through a transport
module, which comprises of 71 metabolites, 70 reactions, and
41 genes (including 19 newly added genes). These additional
transport reactions are for amino acids (27 reactions), lipids
(16 reactions), nucleosides (6 reactions), vitamins and miner-
als (8 reactions), hormones (6 reactions), and others (7 reac-
tions). In addition, 24 Recon 2 reactions need to be updated
with respect to their gene-protein-reaction associations pro-
vided in Supplemental Table S2. Details of the transport mod-
ule can be found in Supplemental Table S2 and also at http://
humanmetabolism.org. Overall, the transport module summa-
rizes in a computer-readable, structured manner all transport
systems, and their corresponding reactions, that we discovered
to be missing from Recon 2 (Figure 1H). This module is thus
an extension to Recon 2, which can be added to the existing
reconstruction if desired.
TRANSPORT PROTEINS ASSOCIATED WITH DISEASES
Transporters fulfill a broad range of functions, which go far
beyond the sole movement of metabolites. In our discussion
on the transport of distinct metabolite classes, many of these
functions have been mentioned. Targeting specific transport pro-
teins to combat disease conditions, such as cholestasis (Wagner
and Trauner, 2005), neurodegenerative disorders (Hinoi et al.,
2005), cystic fibrosis (Amaral and Kunzelmann, 2007), cancer (Lo
et al., 2008; Ganapathy et al., 2009), cerebral ischemia (Kimelberg,
2005), diabetes, and secretory diarrhea (Wright et al., 2007), have
gained considerable attention in recent years. Herein, we will
focus on the discussion of transport proteins in disease groups
concerning IEMs and cancer.
Transport proteins associated with metabolic diseases
Metabolic disorders are associated with disrupted cellu-
lar metabolism. IEMs are hereditary metabolic disorders,
caused by specific mutations in genes encoding metabolic
enzymes/transporters. We have recently mapped more than 200
IEMs onto the two human GENREs (Sahoo et al., 2012; Thiele
et al., 2013). Of these, 14% (Table 4) were caused by faulty
transport systems, including 15 IEM-causative genes associated
with ABC transporters and 22 IEM-causative genes associated
with SLC transporters. One good example for an IEM caused
by a faulty transport system is lysinuric protein intolerance
(OMIM: 222700). This disorder is caused by mutations in
the gene encoding the y+ LAT1 amino acid transport system
(SLC7A7, GeneID: 9056). Although rare (mostly observed in
the Finish and Japanese populations, with incidence of 1:60,000
live births), this IEM has a clinical picture of recurrent diarrhea,
vomiting, and in the long-term affects the immune system,
www.frontiersin.org March 2014 | Volume 5 | Article 91 | 15
Sahoo et al. Membrane transporters in human metabolic reconstructions
Table 4 | Metabolic diseases associated with transport proteins.
EntrezGene ID Transporter name Diseases with a defect in a transport protein References
19 ATP-binding cassette
sub-family A member 1
Tangier disease OMIM: 205400
5244 MRP3 Progressive familial intrahepatic cholestasis, biliary gallstone disease,
intrahepatic cholestasis of pregnancy
OMIM: 171060
6342 SCP2 Zellweger syndrome and Leukoencephalopathy with dystonia and motor
neuropathy
OMIM: 184755
6505 EAAT3 Dicarboxylic aminoaciduria OMIM: 222730, (Teijema
et al., 1974)
6513 GLUT1 GLUT1 deficiency syndrome OMIM: 606777
6514 GLUT2 Fanconi-Bickel syndrome OMIM: 227810
6519 rBAT Cystinuria OMIM: 220100
6523 SGLT1 Glucose-galactose malabsorption OMIM: 606824
6524 SGLT2 Renal glucosuria OMIM: 233100
6555 Ileal sodium/bile acid
cotransporter
Primary bile acid malabsorption OMIM: 613291
6584 OCTN2 Systemic carnitine deficiency OMIM: 212140
8647 Bile salt export pump Benign recurrent intrahepatic cholestasis-2 OMIM: 603201
9056 y+LAT-1/4f2hc Lysinuric protein intolerance OMIM: 222700
9152 GLYT2 Hyperekplexia OMIM: 614618, (Tijssen
and Rees, 1993)
10560 ThTr1 Thiamin-responsive megaloblastic anemia syndrome OMIM: 249270
10599 OATP-C Rotor type hyperbilirubinemia OMIM: 604843
10999 FATP-4 Ichthyosis prematurity syndrome (IPS) OMIM: 608649
11001 FATP-2 Milder variant of X-linked adrenoleukodystrophy OMIM: 603247
11136 b0,+AT Cystinuria OMIM: 220100
55315 ENT3 Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial
Rosai-Dorfman Disease
OMIM: 602782, (Barnes
et al., 2006; Morgan et al.,
2010)
56606 GLUT9 Renal hypouricemia-2 OMIM: 612076
113235 PCFT Hereditary folate malabsorption OMIM: 229050, (Diop-Bove
et al., 1993)
1244 MRP2 Dubin-Johnson syndrome OMIM: 237500, (Kanda
et al., 2009)
8029 Cubilin Hereditary megaloblastic anemia 1 (MGA1) OMIM: 261100, (Kristiansen
et al., 2000)
54716 Sodium- and
chloride-dependent
transporter XTRP3
Iminoglycinuria OMIM: 242600
21 ATP-binding cassette
sub-family A member 3
Pulmonary surfactant metabolism dysfunction type 3 (SMDP3) OMIM: 610921, (Wert et al.,
2009)
24 Retinal-specific ATP-binding
cassette transporter
Stargardt disease, a form of juvenile-onset macular degeneration,
retinitis pigmentosa-19, cone-rod dystrophy type 3, early-onset severe
retinal dystrophy, fundus flavimaculatus, and macular degeneration
age-related 2
OMIM: 248200
359 AQP2 Nephrogenic diabetes insipidus OMIM: 125800, OMIM:
304800, (Knoers, 1993)
364 AQP7 Several metabolic alterations including obesity, type 2 diabetes OMIM: 125853, (Prudente
et al., 2007)
949 SRB-I Familial hypercholesterolemia OMIM: 601040
2638 DBP Graves disease OMIM: 139200
4036 Megalin Donnai-Barrow syndrome OMIM: 222448, (Kantarci
et al., 1993; Pober et al.,
2009)
(Continued)
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Table 4 | Continued
EntrezGene ID Transporter name Diseases with a defect in a transport protein References
5243 MRP1 Crohn’s disease OMIM: 171050
6833 ATP-binding cassette
sub-family C member 8
Hyperinsulinemic hypoglycemia of infancy, non-insulin-dependent
diabetes mellitus type II
OMIM: 256450, OMIM:
125853, (Glaser, 1993)
6891 TAP 2 Ankylosing spondylitis, insulin-dependent diabetes mellitus, and celiac
disease
OMIM: 170261
9429 ATP-binding cassette
sub-family G member 2
Gout OMIM: 138900
10058 ATP-binding cassette
sub-family B member 6,
mitochondrial
This gene is considered to be a candidate gene for lethal neonatal
metabolic syndrome, a disorder of mitochondrial function.
OMIM: 605452
10060 ATP-binding cassette
sub-family C member 9
Dilated cardiomyopathy OMIM: 601439
26154 ATP-binding cassette
sub-family A member 12
Lamellar ichthyosis type 2, Harlequin ichthyosis OMIM: 607800, (Mitsutake
et al., 2010),
29881 Niemann-Pick C1-like
protein 1
Multiple lipid transport defects OMIM: 608010, (Polisecki
et al., 2010)
64240 ATP-binding cassette
sub-family G member 5
Sitosterolemia OMIM: 210250
64241 ATP-binding cassette
sub-family G member 8
Sitosterolemia OMIM: 210250
116085 URAT1 Renal hypouricemia-1 OMIM: 220150
153201 Proton-coupled amino acid
transporter 2
Iminoglycinuria and hyperglycinuria OMIM: 242600
340024 B(0)AT1 Hartnup disorder OMIM: 234500
The color coding is the same as in Table 1.
skeletal system, and pulmonary and renal function, which
can even lead to the death if left untreated. Specific dietary
recommendations include protein restriction and citrulline and
lysine supplementation. Recon 1 captured 22 of the 45 plasma
membrane transport protein-associated IEMs genes. Recon 2
captured three additional diseases/genes. The remaining 20
transport protein-associated IEMs could not be mapped onto
Recon 2 due to missing genes (see Table 4 for details). The
IEMs for the ABC class of transporters account for 33% of
these missing IEMs. The non-inclusion of the ABC transport
proteins into human GENREs is because they have been shown to
transport mainly medically important drugs and their derivatives
(e.g., ABCB1, GeneID: 5243, ABCG2, GeneID: 9429) or that
insufficient information on the preferred substrates is available
(e.g., for ABCF3, GeneID: 55324). However, another major pro-
portion of the missed IEMs/genes concerns fat-soluble vitamins
and lipids (e.g., SRB-I, Niemann-Pick C1-like protein 1), for
which transport mechanisms have only been partially resolved
(see the relevant sections above). Therefore, we would like to
emphasize the need to have sufficient information regarding
the preferred substrates, associated cofactors/ions, substrate:ion
stoichiometry, transport kinetics, and sub-cellular localization of
transport proteins for building a high quality reconstruction of
the transport reactions/pathways.
Transport proteins associated with cancer
Cancer cells reprogram metabolic pathways to support their
increased need for energy and biosynthetic precursors (Cairns
et al., 2011). The metabolic characteristics of cancer cells are the
high uptake of glucose, aerobic glycolysis, secretion of lactate
(Warburg effect), and a high rate of glutaminolysis to compen-
sate for the efflux of TCA cycle intermediates into biosynthetic
pathways (Feron, 2009). Alternations in metabolite uptake (e.g.,
amino acids and glucose) and secretion through specific sets of
transporters constitute key factors for how these continuously
proliferating cells meet their metabolic demands (Ganapathy
et al., 2009). As discussed above, redundancy and overlapping
substrate specificity exist within and between transporter fam-
ilies. Cancer cells have to operate sets of transporters that best
nourish their metabolic dependencies. In fact, the distinctive
transporter expression between cancerous and normal cells could
provide good opportunities for targeted treatment (Ganapathy
et al., 2009). The contribution of transporters of the metabolite
classes in cancer discussed above has been reviewed elsewhere
(Fuchs and Bode, 2005; Verkman et al., 2008; Ganapathy et al.,
2009; Calvo et al., 2010; Fletcher et al., 2010) and is summarized
in Table 5.
Coverage and accurate representation of transport systems are
essential to perform valuable simulations using COBRA. Recon 1
has been used for the generation and analysis of cancer-specific
metabolic models (Folger et al., 2011; Frezza et al., 2011; Jerby
et al., 2012; Wang et al., 2012b) and has been recently summa-
rized (Jerby and Ruppin, 2012; Hernández Patiño et al., 2013). Of
the 20 extracellular transporters (Table 5) that play a role in can-
cer metabolic reprogramming and proliferation, 13 transporters
are correctly represented in Recon 2 (Table 5), three need to be
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Table 5 | Metabolite transporters relevant to cancer and their current coverage in Recon 2.
Entrez Gene ID Transporters Substrates Reference
4363 MRP1 (ABCC1) Xenobiotics, cytotoxic drugs Fletcher et al., 2010
6510 ASCT2 (SLC1A5) Glutamine Fuchs and Bode, 2005; Ganapathy et al., 2009
6513 GLUT1 Glucose Ganapathy et al., 2009
6515 GLUT3 Glucose Ganapathy et al., 2009
6566 SLC16A1/MCT1 Lactate Pouyssegur et al., 2006; Ganapathy et al., 2009
6584 OCTN2 (SLC22A5) Carnitine Scalise et al., 2012; Wang et al., 2012a
8884 SMVT Biotin Vadlapudi et al., 2012
9123 SLC16A4/MCT4 Lactate Pouyssegur et al., 2006; Ganapathy et al., 2009
9194 SLC16A2/MCT2 Lactate Pouyssegur et al., 2006; Ganapathy et al., 2009
23539 SLC16A3/MCT3 Lactate Pouyssegur et al., 2006; Ganapathy et al., 2009
23657, 6520 xCT (SLC7A11)/ 4F2hc (SLC3A2) Cysteine Fuchs and Bode, 2005; Ganapathy et al., 2009
80704 SLC19A3 Thiamin Sweet et al., 2010
154091 GLUT12 Glucose Ganapathy et al., 2009
6523 SGLT1 Glucose Ganapathy et al., 2009
8140, 6520 LAT1 (SLC7A5)/ 4F2hc (SLC3A2) Glutamine/cysteine antiport Fuchs and Bode, 2005; Ganapathy et al., 2009
11254 ATB0,+ (SLC6A14) Proteinogenic amino acids except
glutamate and aspartate
Ganapathy et al., 2009
360 AQP3 Glycerol Hara-Chikuma and Verkman, 2008; Verkman et al., 2008
5243 MDR1 (ABCB1) Xenobiotics, cytotoxic drugs Fletcher et al., 2010
9429 ABCG2 Xenobiotics, cytotoxic drugs Fletcher et al., 2010
160728 SLC5A8/SMCT-1 Lactate, pyruvate, and butyrate
(gut microbes)
Thangaraju et al., 2006, 2008; Ganapathy et al., 2009
The color coding is the same as in Table 1.
modified, and four are still missing or require further curation.
This section discusses the cancer relevant transporters currently
missing or requiring revision (Table 5).
The pyruvate to lactate conversion is necessary to sustain a high
glycolytic flux (Feron, 2009). The accumulation of lactate and a
decreasing pyruvate level put cell survival at risk due to increasing
acidification of the cytoplasm.Cancer cells counteract the decrease
in intracellular pH by specific ion transport (i.e., bicarbonate
and protons) and lactate export via lactate/H+ symport, which
is mediated by one of the four MTC transporters (SLC16A1,
GeneID: 6566; SLC16A7 GeneID: 9194; SLC16A8 GeneID: 23539;
SLC16A4 GeneID: 9122). The high affinity lactate transporter
SMCT1 (SLC5A8, GeneID: 160728) favors the import of lactate
(Gopal et al., 2004) and is suppressed in a number of cancer cell
types, as summarized in (Ganapathy et al., 2009). For example,
SLC5A8 is silenced by methylation in human astrocytomas and
oligodendrogliomas (Hong et al., 2005) and in primary colon
cancers and colon cancer cell lines (Li et al., 2003). In addition to its
transporter function, the SLC5A8 protein has a demonstrated role
in tumor suppression through the active import of endogenous
inhibitors of histone acetylases (HDACs) [i.e., butyrate, which
originates from gut microbes, and pyruvate (Thangaraju et al.,
2006, 2008)]. Recently, SLC5A8 was shown to counteract tumor
progression independent from its transport function. Instead,
SLC5A8acts throughanunknownmechanisminvolvingadecrease
in the anti-apoptotic protein survivin (Coothankandaswamyet al.,
2013). Recon 2 includes passive iodide transport via SLC5A8 and
the Na+-coupled transport of lactate, pyruvate, and the short-
chain fatty acids acetate, propionate, and butyrate (Miyauchi et al.,
2004) (Table 5). Hence, these data were added in the transport
module (Supplemental Table S2). SLC5A8 was not included in
Recon2,most likely because this proteinhas beenmainlydiscussed
in the context of cancer.
ABC transporters mediate the efflux of cytotoxic drugs,
causing multidrug resistance (MDR) and chemotherapy failure
(Fletcher et al., 2010; Falasca and Linton, 2012). Two of the four
major drug transporters, MDR1 (ABCB1, GeneID: 5243) and
ABCG2 (ABCG2, GeneID: 9429), are missing in Recon 2 (see
also the IEMs section). Both are known to be overexpressed in
different cancer types (Fletcher et al., 2010). A subpopulation
of cancer cells with enriched stem cell activity, so called side
populations (SPs), have been extracted from six human lung can-
cer cell lines (H460, H23, HTB-58, A549, H441, and H2170).
When tested for an elevation in ABC transporter expression, all
of the SPs displayed a significantly higher mRNA expression for
ABCG2 compared to their non-SP counterparts (Ho et al., 2007).
Four SPs also showed a significantly higher expression for MDR1
transporters. All six showed resistance to exposure to different
chemotherapeutic drugs. The survival of such cells with stem cell
activity upon drug treatment could be connected to a relapse
in vivo (Ho et al., 2007), and ABC transporter expression might
be an indicators for this cancer cell phenotype.
Strong expression of aquaporins has been observed in vari-
ous tumors, especially aggressive tumors (Verkman et al., 2008).
Some aquaporins are exclusively expressed in malignant tissue
(Verkman et al., 2008). The aquaglyceroporin aquaporin-3, AQP3
(AQP3, GeneID: 360), which also transports glycerin in addi-
tion to water, is expressed in normal epidermis and overexpressed
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in basal cell carcinoma and human skin squamous cell carci-
nomas (Hara-Chikuma and Verkman, 2008). AQP3-facilitated
glycerol transport was found to determine cellular ATP levels and
therefore be important for hyperproliferation and tumor cell pro-
liferation in epidermal mice cells (Hara-Chikuma and Verkman,
2008). Correspondingly, the resistance of AQP3 null-mice toward
skin tumors might arise through reduced tumor cell glycerol
metabolism and ATP generation (Hara-Chikuma and Verkman,
2008). This property renders AQP3 inhibition a possible target for
the prevention and treatment of skin, and possibly other cancers
associated with aquaglyceroporin overexpression (Hara-Chikuma
and Verkman, 2008). AQP3 is currently missing in Recon 2 and
covered in the transport module.
Although many of the transporters associated with cancer
are present in Recon 2 (Table 5), important mediators of intra-
and extracellular pH, drug resistance, and proliferative energy
metabolism are still missing.
CONCLUSION
A great deal of work in the field of constraint-based modeling has
focused on the generation of highly curated GENREs and their
usage for the generation of tissue-specific metabolic models for
biomedical applications.
Transporters not only maintain the connectivity of metabo-
lites across different cell types but also determine the uptake and
secretion profile of individual cells. The metabolite exchanges
of individual cell types with the corresponding extracellular
compartment are inevitably connected to their internal bio-
chemical pathways and cell functions. The inclusion of the cell
type-specific transporters is important for enabling the use of the
human metabolic reconstruction as a template for the generation
of more accurate and physiologically relevant cell type-specific
sub-networks and ultimately function-representative models.
Moreover, information regarding distinct transporter function at
different locations, as is the case for polarized cells, is crucial for
such an effort and has thus been noted throughout this review.
We identified numerous gaps through our literature review, many
of which could be filled and are provided in the accompanying
transport module. However, some knowledge gaps still remain
because the responsible transporter or transport mechanism is
unknown. Such a knowledge update for the GENRE needs to be
performed periodically because of the important implications on
their predictive potential (Thiele and Palsson, 2010b) and thus
biomedical applications.
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